Four PI3K inhibitors have also been FDA-approved (Figure 1): the two benzopyrimidinones idelalisib and duvelisib (PI3K δ and γ-selective) for three types of blood cancer hematologic malignancy or chronic lymphocytic leukemia, respectively [27,28] as well as the tricyclic heterocyclic copanlisib (PI3K α and δ-selective) for follicular lymphoma [29]. Here, PIK3CA is linked to hematopoietic and lymphoid system neoplasm.